Form 4: Erasca Director Jean I Liu Granted 120,000 Stock Options

Erasca, Inc. Director Jean I Liu was granted 120,000 stock options with an exercise price of $1.45, vesting fully on June 24, 2026.

Summary

• Jean I Liu, a Director of Erasca, Inc. (ERAS), was granted 120,000 stock options.
• The options have an exercise price of $1.45 per share.
• 100% of the options are scheduled to vest on June 24, 2026, contingent upon Ms. Liu's continuous service to the Issuer.
• The granted options have an expiration date of June 23, 2035.
• Following this transaction, Ms. Liu directly beneficially owns 120,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a routine stock option grant to a director, which is a positive signal of alignment between the board and shareholder interests. It does not contain any negative operational or financial news, nor does it suggest any immediate concerns.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and value creation for Erasca, Inc. shareholders.
• The options have a long expiration date of June 23, 2035, providing ample time for potential stock price appreciation above the exercise price.

Risks

• The value of the granted stock options is entirely dependent on Erasca, Inc.'s common stock price exceeding the exercise price of $1.45 per share.
• The vesting of the options is subject to the reporting person's continuous service to the Issuer, meaning the options could be forfeited if service terminates before the vesting date.

Future Outlook

The grant of stock options serves as a long-term incentive for the director, aligning their future compensation with the company's stock performance and strategic objectives through the option's expiration in 2035.

Industry Context

Stock option grants are a standard component of executive and director compensation packages across various industries, particularly in growth-oriented sectors like biotechnology. This practice aims to incentivize long-term performance, retention, and align the interests of key personnel with those of shareholders. This specific grant is consistent with typical compensation structures for directors in publicly traded companies.

Comparison to Industry Standards

• The grant of stock options to a director is a common and widely accepted practice for public companies, especially within the biotechnology sector where long-term value creation is paramount.
• While the specific number of options granted can vary significantly based on company size, market capitalization, and the individual's role and responsibilities, the mechanism of equity-based compensation is a global benchmark for aligning director incentives with shareholder returns.
• No specific comparable companies or projects are detailed in this filing to provide a direct numerical comparison of the grant size, but the nature of the compensation is consistent with industry standards.

Stakeholder Impact

• **Shareholders:** The grant aligns the director's financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price appreciates above the exercise price.
• **Employees:** No direct impact on general employees from this specific filing.

Next Steps

• Monitoring the company's stock performance relative to the option exercise price of $1.45.
• Observing the director's continuous service to ensure the vesting of the options on June 24, 2026.

Key Dates

Keywords

Erasca Inc., ERAS, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Jean I Liu